Information de reference pour ce titreAccession Number: | 00062752-201305000-00009.
|
Author: | Itkin, Tomer a; Kaufmann, Kerstin B. b; Gur-Cohen, Shiri a; Ludin, Aya a; Lapidot, Tsvee a
|
Institution: | (a)Department of Immunology, Weizmann Institute of Science, Rehovot, Israel (b)Institute for Biomedical Research, Georg-Speyer-Haus, Frankfurt, Germany
|
Title: | |
Source: | Current Opinion in Hematology. 20(3):237-244, May 2013.
|
Abstract: | Purpose of review: Fibroblast growth factor (FGF) signaling activates many bone marrow cell types, including various stem cells, osteoblasts, and osteoclasts. However, the role of FGF signaling in regulation of normal and leukemic stem cells is poorly understood. This review highlights the physiological roles of FGF signaling in regulating bone marrow mesenchymal and hematopoietic stem and progenitor cells (MSPCs and HSPCs) and their dynamic microenvironment. In addition, this review summarizes the recent studies which provide an overview of FGF-activated mechanisms regulating physiological stem cell maintenance, self-renewal, and motility.
Recent findings: Current results indicate that partial deficiencies in FGF signaling lead to mild defects in hematopoiesis and bone remodeling. However, FGF signaling was shown to be crucial for stem cell self-renewal and for proper hematopoietic poststress recovery. FGF signaling activation was shown to be important also for rapid AMD3100 or post 5-fluorouracil-induced HSPC mobilization. In vivo, FGF-2 administration successfully expanded both MSPCs and HSPCs. FGF-induced expansion was characterized by enhanced HSPC cycling without further exhaustion of the stem cell pool. In addition, FGF signaling expands and remodels the supportive MSPC niche cells. Finally, FGF signaling is constitutively activated in many leukemias, suggesting that malignant HSPCs exploit this pathway for their constant expansion and for remodeling a malignant-supportive microenvironment.
Summary: The summarized studies, concerning regulation of stem cells and their microenvironment, suggest that FGF signaling manipulation can serve to improve current clinical stem cell mobilization and transplantation protocols. In addition, it may help to develop therapies specifically targeting leukemic stem cells and their supportive microenvironment.
(C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
|
Author Keywords: | expansion; FGF-2; FGFR; hematopoietic stem cells; microenvironment.
|
References: | 1. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425:841-846.
2. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425:836-841.
3. Kollet O, Dar A, Shivtiel S, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006; 12:657-664.
4. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25:977-988.
5. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466:829-834.
6. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012; 481:457-462.
7. Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol 2006; 34:967-975.
8. Taichman RS, Emerson SG. The role of osteoblasts in the hematopoietic microenvironment. Stem Cells 1998; 16:7-15.
9. Sabbieti MG, Agas D, Xiao L, et al. Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol 2009; 219:143-151.
10. Ortega S, Ittmann M, Tsang SH, et al. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci USA 1998; 95:5672-5677.
11. Poole TJ, Finkelstein EB, Cox CM. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn 2001; 220:1-17.
12. Yamazaki S, Ema H, Karlsson G, et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011; 147:1146-1158.
13. Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010; 6:251-264.
14. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 2005; 20:349-356.
15. Okada Y, Montero A, Zhang X, et al. Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. J Biol Chem 2003; 278:21258-21266.
16. Lymperi S, Ersek A, Ferraro F, et al. Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood 2011; 117:1540-1549.
17. Li JY, Adams J, Calvi LM, et al. PTH expands short-term murine hemopoietic stem cells through T cells. Blood 2012; 120:4352-4362.
18. Yeoh JS, van Os R, Weersing E, et al. Fibroblast growth factor-1 and -2 preserve long-term repopulating ability of hematopoietic stem cells in serum-free cultures. Stem Cells 2006; 24:1564-1572.
19. De Haan G, Weersing E, Dontje B, et al. In vitro generation of long-term repopulating hematopoietic stem cells by fibroblast growth factor-1. Dev Cell 2003; 4:241-251.
20. Kashiwakura I, Takahashi TA. Fibroblast growth factor and ex vivo expansion of hematopoietic progenitor cells. Leuk Lymphoma 2005; 46:329-333.
21. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002; 8:483-489.
22. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16:159-178.
23. D'Amore PA. Modes of FGF release in vivo and in vitro. Cancer Metastasis Rev 1990; 9:227-238.
24. Chen PY, Qin L, Barnes C, et al. FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep 2012; 2:1684-1696.
25. Slukvin II, Vodyanik M. Endothelial origin of mesenchymal stem cells. Cell Cycle 2011; 10:1370-1373.
26[black small square]. Ma J, Hou Y, Han D, et al. Fibroblast growth factor-peptide promotes bone marrow recovery after irradiation. Adv Exp Med Biol 2013; 765:155-161.
27. Yamaguchi TP, Harpal K, Henkemeyer M, Rossant J. Fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev 1994; 8:3032-3044.
28[black small square][black small square]. Itkin T, Ludin A, Gradus B, et al. FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation. Blood 2012; 120:1843-1855.
29[black small square][black small square]. Zhao M, Ross JT, Itkin T, et al. FGF signaling facilitates postinjury recovery of mouse hematopoietic system. Blood 2012; 120:1831-1842.
30. Montero A, Okada Y, Tomita M, et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 2000; 105:1085-1093.
31. Coutu DL, Galipeau J. Roles of FGF signaling in stem cell self-renewal, senescence and aging. Aging (Albany NY) 2011; 3:920-933.
32. Hurley MM, Okada Y, Xiao L, et al. Impaired bone anabolic response to parathyroid hormone in Fgf2-/- and Fgf2+/- mice. Biochem Biophys Res Commun 2006; 341:989-994.
33. Catlin SN, Busque L, Gale RE, et al. The replication rate of human hematopoietic stem cells in vivo. Blood 2011; 117:4460-4466.
34. Miyamoto K, Araki KY, Naka K, et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007; 1:101-112.
35. Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006; 12:446-451.
36[black small square]. Abbas HA, Maccio DR, Coskun S, et al. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell 2012; 7:606-617.
37. Fei Y, Xiao L, Hurley MM. The impaired bone anabolic effect of PTH in the absence of endogenous FGF2 is partially due to reduced ATF4 expression. Biochem Biophys Res Commun 2011; 412:160-164.
38[black small square]. Wang X, Guo B, Li Q, et al. miR-214 targets ATF4 to inhibit bone formation. Nat Med 2013; 19:93-100.
39[black small square]. Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 2013; 19:74-82.
40[black small square]. Di Maggio N, Mehrkens A, Papadimitropoulos A, et al. Fibroblast growth factor-2 maintains a niche-dependent population of self-renewing highly potent nonadherent mesenchymal progenitors through FGFR2c. Stem Cells 2012; 30:1455-1464.
41. Coutu DL, Francois M, Galipeau J. Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. Blood 2011; 117:6801-6812.
42. Itkin T, Gur-Cohen S, Ludin A, et al. Endothelial blood-bone marrow-barrier dynamically regulates balanced stem and progenitor cell trafficking and maintenance [abstract]. ASH Annual Meeting Abstracts 2012; 120:507.
43. Fuks Z, Persaud RS, Alfieri A, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994; 54:2582-2590.
44. Pena LA, Fuks Z, Kolesnick RN. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 2000; 60:321-327.
45. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009; 8:580-588.
46. Menzel T, Rahman Z, Calleja E, et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996; 87:1056-1063.
47. Konig A, Menzel T, Lynen S, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997; 11:258-265.
48. Karajannis MA, Vincent L, Direnzo R, et al. Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia 2006; 20:979-986.
49. Gu TL, Goss VL, Reeves C, et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 2006; 108:4202-4204.
50. Bieker R, Padro T, Kramer J, et al. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res 2003; 63:7241-7246.
51. Moroni E, Dell'Era P, Rusnati M, Presta M. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res 2002; 11:19-32.
52. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96:2240-2245.
53. Colmone A, Amorim M, Pontier AL, et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008; 322:1861-1865.
54. Ge J, Hou R, Liu Q, et al. Stromal-derived factor-1 deficiency in the bone marrow of acute myeloid leukemia. Int J Hematol 2011; 93:750-759.
55. Molica S, Vacca A, Levato D, et al. Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res 2004; 28:321-324.
56. Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009; 23:2233-2241.
57. Seke Etet PF, Vecchio L, Nwabo Kamdje AH. Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways? Cell Signal 2012; 24:1433-1443.
58. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107:1761-1767.
59. Sipkins DA, Wei X, Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005; 435:969-973.
60. Ribatti D, Scavelli C, Roccaro AM, et al. Hematopoietic cancer and angiogenesis. Stem Cells Dev 2004; 13:484-495.
61[black small square]. Levesque JP, Winkler IG, Rasko JE. Nichotherapy for stem cells: there goes the neighborhood. Bioessays 2013; 35:183-190.
62. Hall SL, Lau KH, Chen ST, et al. Sca-1(+) hematopoietic cell-based gene therapy with a modified FGF-2 increased endosteal/trabecular bone formation in mice. Mol Ther 2007; 15:1881-1889.
63. Meng X, Baylink DJ, Sheng M, et al. Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation. PLoS One 2012; 7:e37569.
64. Paciaroni M, Bogousslavsky J. Trafermin for stroke recovery: is it time for another randomized clinical trial? Expert Opin Biol Ther 2011; 11:1533-1541.
|
Language: | English.
|
Document Type: | VASCULAR BIOLOGY: Edited by Thomas F. Deuel.
|
Journal Subset: | Nursing. Clinical Medicine.
|
ISSN: | 1065-6251
|
NLM Journal Code: | cn0, 9430802
|
DOI Number: | https://dx.doi.org/10.1097/MOH.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|